Pricing Log in Create free account

Fate Therapeutics, Inc. (FATE) vs Sol-Gel Technologies Ltd. (SLGL)

Fate Therapeutics, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Fate Therapeutics, Inc. and Sol-Gel Technologies Ltd. are of similar size ($230.7M and $224.9M). Fate Therapeutics, Inc. grew revenue faster over the last twelve months: −23.4% against −92.5%. Sol-Gel Technologies Ltd. has the higher net margin (−910.1% vs −1,941.1%) and the lower return on invested capital (−6,630.2% vs 0.00%). Across the 16 metrics below, Sol-Gel Technologies Ltd. leads on 10 and Fate Therapeutics, Inc. on 6.

Valuation

Metric FATE SLGL Biotechnology median
P/E n/m n/m 8.50
P/S 33.20 117.08 9.71
P/B 1.40 4.37 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 13.12 126.78 9.21
Earnings yield (58.66%) (8.78%) (33.15%)
Free cash flow yield (48.92%) (10.12%) (25.50%)

Profitability

Metric FATE SLGL Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (2,058.08%) (986.96%) 0.00%
Net margin (1,941.09%) (910.14%) 0.00%
Free cash flow margin (1,624.06%) (1,185.18%) 0.00%
Return on equity (60.75%) (40.85%) (56.36%)
Return on assets (39.89%) (35.11%) (48.04%)
Return on invested capital 0.00% (6,630.24%) 0.00%

Growth

Metric FATE SLGL Biotechnology median
Revenue growth (TTM) (23.36%) (92.50%) 6.02%
EPS growth (last fiscal year) 29.88% 42.37% 30.26%
Revenue growth, 5-year CAGR (26.71%) 17.19% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FATE SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.85 10.37 4.72
Net debt to EBITDA 1.47 3.23 0.96

Dividend

Metric FATE SLGL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric FATE SLGL Biotechnology median
Market cap 230.65m 224.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack